- Dubai Struggles to Ease Debt Fears; Investors Rattled
- US Dollar Falls to 14-Year Low Against the Yen
- US Companies Already Moving on Curbing Emissions
- Fannie Mae to Tighten Lending Standards: Report
- Investing in Good Karma – and Making a Profit
- Retailers Should Believe in Christmas Miracles
- Bankruptcies Jump, Hitting Highest Level in Four Years
- Steepest Black Friday Discounts, Revealed
- Lloyds Gets OK for Record $22.5 Billion Rights Issue
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
MOST SHARED
- Kuoni CEO Sees Recovery in Travel Sector
- Gold Retreats from Record High as Dollar Rebounds
- Dubai Struggles to Ease Debt Fears; Investors Rattled
- China Unveils Carbon Target Ahead of Copenhagen
- Wal-Mart Price Pressure Hurts China Workers: Report
- Chinese Overcapacity is Worsening, EU Chamber Warns
- Euro Shares Record Biggest Drop in 7 Months
- Great Britain, No Longer That Great: Investor
- Hyundai-Kia Targets Rapid China Growth in 2010
- Fannie Mae to Tighten Lending Standards: Report
Text Size 
Swedish drug company Meda said on Friday it signed an $800 million cash-and-stock deal to buy allergy and pain treatment specialist MedPointe. from a group of U.S. investors.
Meda said it would pay $520 million in cash and 17.5 million newly issued Meda shares worth some 1.9 billion Swedish crowns ($286.3 million) based on Friday's 108.5 crown opening price for the stock for the New Jersey-based company.
Meda shares surged on the news, trading nearly 12% higher at 115.75 crowns as of 0727 GMT. "It looks very interesting," said Johan Unnerus, analyst at Swedbank.
"They enter an entirely new market. The price is relatively high compared with earlier acquisitions, but as there is good growth and a lot of product development, that shouldn't be seen as negative," he added.
MedPointe's biggest products are non-steroidal nasal spray Astelin and the allergic conjunctivitis treatment Optivar, Meda said in a statement.
Privately owned MedPointe's sales were $252 million in 2006 with an EBITDA (earnings before interest, taxes, depreciation and amortisation) margin of 12%, reflecting high costs related to marketing and clinical development, Meda said.
Gross margins, however, were 90%, the company added. The Swedish company said the MedPointe buy will add to its earnings per share by 2009 at the latest.
The transaction will mean that MedPointe owners Carlyle and Cypress groups and some additional U.S. investors hold about 6% of Meda's shares.
"The acquisition looks positive. They will get more distribution capacity, "said one trader who declined to be identified.
Meda Chief Executive Anders Lonner said the merger made sense from both the marketing and product pipeline standpoints.
"The new product development from both companies can now be utilized in the company instead of being out-licensed, "Lonnersaid. "The product development investment done by MedPointe will represent strong growth potential both on top line and profit."MedPointe has a staff of 710.
Print
Email
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
- Ever wished your cab driver would stop nattering and just get to where you're going? Well that moment is near(er).
- Eric Schmidt pledges to create a virtual copy of the Iraq National Museum at Google’s expense.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- More shoppers than ever plan to comparison-shop this season. Who will benefit?
- It may be the most unusual guide to business you'll read.
Data is a real-time snapshot *Data is delayed at least 15 minutes